Pregabalin in clinical psychiatry and addiction: Pros and cons

Expert Opinion on Investigational Drugs

Volumn 21, Issue 9, 2012, Pages 1243-1245

  Martinotti, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Addiction; Anxiety; Calcium channels; Pregabalin

Indexed keywords

BENZODIAZEPINE; PREGABALIN; VOLTAGE GATED CALCIUM CHANNEL;

ADDICTION; ALCOHOLISM; ANXIETY DISORDER; DIARRHEA; DRUG DEPENDENCE; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NEUROTRANSMITTER RELEASE; PSYCHIATRY; REVIEW; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME;

ALCOHOLISM; ANTICONVULSANTS; ANXIETY DISORDERS; BENZODIAZEPINES; CALCIUM CHANNELS; GAMMA-AMINOBUTYRIC ACID; HUMANS; SUBSTANCE-RELATED DISORDERS;

EID: 84865344642     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.703179     Document Type: Review

References (21)

1. Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73(2):137-50 (Pubitemid 46329329)
2. Pexton T, Moeller-Bertram T, Schilling JM, et al. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development. Expert Opin Investig Drugs 2011;20(9):1277-84
3. Boschen MJ. A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder. Can J Psychiatry 2011;56(9):558-66
4. Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011;26(4):213-20
5. Di Nicola M, Tedeschi D, Martinotti G, et al. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series. J Clin Psychopharmacol 2011;31(5):675-7
6. Oulis P, Florakis AA, Tzanoulinos G, et al. Adjunctive pregabalin to quetiapine in acute mania. Clin Neuropharmacol 2009;32(3):174
7. Pae CU. Pregabalin augmentation to antidepressants in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009;33(3):577-8
8. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005;28(2):187-93 (Pubitemid 40362644)
9. Forg A, Hein J, Volkmar K, et al. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol 2012;47(2):149-55
10. Martinotti G, di Nicola M, Frustaci A, et al. Pregabalin, tiapride and lorazepam in alcohol withdrawal syndrome: a multi-centre, randomized, single-blind comparison trial. Addiction 2010;105(2):288-99
11. Martinotti G, Di Nicola M, Tedeschi D, et al. Efficacy and safety of pregabalin in alcohol dependence. Adv Ther 2008;25(6):608-18
12. Martinotti G, Di Nicola M, Tedeschi D, et al. Pregabalin versus naltrexone in alcohol dependence: a randomised, double-blind, comparison trial. J Psychopharmacol 2010;24(9):1367-74
13. Stopponi S, Somaini L, Cippitelli A, et al. Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat. Psychopharmacology (Berl) 2012;220(1):87-96
14. Bobes J, Rubio G, Teran A, et al. Pregabalin for the discontinuation of long-term benzodiazepines use: an assessment of its effectiveness in daily clinical practice. Eur Psychiatry 2011;Published online 18 February 2011
15. Oulis P, Konstantakopoulos G, Kouzoupis AV, et al. Pregabalin in the discontinuation of long-term benzodiazepines' use. Hum Psychopharmacol 2008;23(4):337-40 (Pubitemid 351982672)
16. Harmark L, van Puijenbroek E, Straus S, et al. Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information. Drug Saf 2011;34(3):221-31
17. Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012;Published online 12 April 2012
18. Schwan S, Sundstrom A, Stjernberg E, et al. A signal for an abuse liability for pregabalin-results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol 2010;66(9):947-53
19. Schifano F, D'Offizi S, Piccione M, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom 2011;80(2):118-22
20. Schifano F, Leoni M, Martinotti G, et al. Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. Cyberpsychol Behav 2003;6(4):405-10 (Pubitemid 37087683)
21. Einarsdottir S, Bjornsson E. Pregabalin as a probable cause of acute liver injury. Eur J Gastroenterol Hepatol 2008;20(10):1049